{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:36:17Z","timestamp":1793957777462,"version":"4.8.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":2050,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T00:00:00Z","timestamp":1491868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hypoactive sexual desire disorder (HSDD) is a common sexual disorder in younger and older women. Flibanserin is approved for the treatment of acquired generalized HSDD in premenopausal women only. The efficacy of flibanserin for postmenopausal women with HSDD was demonstrated in the first of two North American randomized, double-blinded, placebo-controlled trials (SNOWDROP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To evaluate the safety and efficacy of flibanserin in postmenopausal women with HSDD in a second randomized, double-blinded, placebo-controlled trial (PLUMERIA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Naturally postmenopausal women were randomly assigned to receive flibanserin (100 mg\/d) or placebo. Efficacy outcomes were assessed using the last-observation-carried-forward imputation method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>Safety assessment included incidence of adverse events. Primary efficacy outcomes were the number of satisfying sexual events and the Female Sexual Function Index desire domain (FSFI-d) score.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study population (flibanserin, n\u00a0= 376; placebo, n\u00a0= 369) included primarily white women (84.7%), with a mean age of 56.1 years and a mean HSDD duration of 5.0 years. When the study was discontinued early by the sponsor, 45.3% of randomly assigned patients had completed week 16 (which served as the primary analysis time point). The most common adverse events in flibanserin-treated patients were insomnia (7.7%), somnolence (6.9%), and dizziness (6.4%). Improvement from baseline to week 16 (last-observation-carried-forward) in FSFI-d score was significantly greater for flibanserin compared with placebo (P\u00a0= .011); however, the between-group comparison for satisfying sexual events did not reach statistical significance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>Considered with the findings of the previous randomized controlled trial (SNOWDROP), the results of this study support the safety and efficacy of flibanserin in postmenopausal women.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>This was a well-designed randomized, placebo-controlled trial. A key limitation was early discontinuation by the study sponsor, which decreased the sample size. In addition, the validity of satisfying sexual events as a primary outcome measurement in HSDD studies has been called into question (but was required by the US Food and Drug Administration as a primary end point in studies of female sexual dysfunction at the time this study was conducted).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Flibanserin was generally well tolerated in this population of naturally postmenopausal women. Despite the greatly decreased power to detect improvement compared with placebo on the efficacy measurements used, results suggest that flibanserin could be efficacious in postmenopausal women with HSDD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1016\/j.jsxm.2017.03.258","type":"journal-article","created":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T20:42:08Z","timestamp":1496522528000},"page":"834-842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Flibanserin in Postmenopausal Women with Hypoactive Sexual Desire Disorder: Results of the PLUMERIA Study"],"prefix":"10.1093","volume":"14","author":[{"given":"David J.","family":"Portman","sequence":"first","affiliation":[{"name":"Columbus Center for Women\u2019s Health Research , Columbus, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Brown","sequence":"additional","affiliation":[{"name":"Valeant Pharmaceuticals North America LLC , Bridgewater, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Yuan","sequence":"additional","affiliation":[{"name":"Valeant Pharmaceuticals North America LLC , Bridgewater, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kissling","sequence":"additional","affiliation":[{"name":"Valeant Pharmaceuticals North America LLC , Bridgewater, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl A.","family":"Kingsberg","sequence":"additional","affiliation":[{"name":"Case Western Reserve University , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,6,1]]},"reference":[{"key":"2023011111053596400_bib1","article-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000","edition":"4th ed"},{"key":"2023011111053596400_bib2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/AOG.0b013e3181898cdb","article-title":"Sexual problems and distress in United States women: prevalence and correlates","volume":"112","author":"Shifren","year":"2008","journal-title":"Obstet Gynecol"},{"key":"2023011111053596400_bib3","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJMoa067423","article-title":"A\u00a0study of sexuality and health among older adults in the United States","volume":"357","author":"Lindau","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"2023011111053596400_bib4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1089\/jwh.2011.3002","article-title":"Sexual desire problems in women seeking healthcare: a novel study design for ascertaining prevalence of hypoactive sexual desire disorder in clinic-based samples of U.S. women","volume":"21","author":"Rosen","year":"2012","journal-title":"J\u00a0Womens Health (Larchmt)"},{"key":"2023011111053596400_bib5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1524-4733.2008.00483.x","article-title":"Hypoactive sexual desire disorder in postmenopausal women: quality of life and health burden","volume":"12","author":"Biddle","year":"2009","journal-title":"Value Health"},{"key":"2023011111053596400_bib6","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40263-015-0288-1","article-title":"The female sexual response: current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of hypoactive sexual desire disorder","volume":"29","author":"Kingsberg","year":"2015","journal-title":"CNS Drugs"},{"key":"2023011111053596400_bib7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3810\/pgm.2010.11.2230","article-title":"Low sexual desire\u2014is it all in her head? Pathophysiology, diagnosis, and treatment of hypoactive sexual desire disorder","volume":"122","author":"Simon","year":"2010","journal-title":"Postgrad Med"},{"key":"2023011111053596400_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1056\/NEJMp1513686","article-title":"FDA approval of flibanserin\u2014treating hypoactive sexual desire disorder","volume":"374","author":"Joffe","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"2023011111053596400_bib9","volume-title":"Addyi\u00ae (flibanserin) tablets, for oral use [package insert]","year":"2016"},{"key":"2023011111053596400_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1017\/S1461145702002869","article-title":"Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain","volume":"5","author":"Marazziti","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"2023011111053596400_bib11","first-page":"15","article-title":"Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder","volume":"8","author":"Stahl","year":"2011","journal-title":"J\u00a0Sex Med"},{"key":"2023011111053596400_bib12","first-page":"1757","article-title":"Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study","volume":"7","author":"Allers","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"2023011111053596400_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1527-3458.2002.tb00219.x","article-title":"Pharmacology of flibanserin","volume":"8","author":"Borsini","year":"2002","journal-title":"CNS Drug Rev"},{"key":"2023011111053596400_bib14","first-page":"1074","article-title":"Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study","volume":"9","author":"Derogatis","year":"2012","journal-title":"J\u00a0Sex Med"},{"key":"2023011111053596400_bib15","first-page":"793","article-title":"Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study","volume":"9","author":"Thorp","year":"2012","journal-title":"J\u00a0Sex Med"},{"key":"2023011111053596400_bib16","first-page":"1807","article-title":"Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial","volume":"10","author":"Katz","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"2023011111053596400_bib17","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1007\/s11606-008-0820-9","article-title":"Correlates of sexual satisfaction among sexually active postmenopausal women in the Women\u2019s Health Initiative\u2013Observational Study","volume":"23","author":"McCall-Hosenfeld","year":"2008","journal-title":"J\u00a0Gen Intern Med"},{"key":"2023011111053596400_bib18","first-page":"301","article-title":"The frequency of sexual intercourse reported by women: a review of community-based studies and factors limiting their conclusions","volume":"5","author":"Schneidewind-Skibbe","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"2023011111053596400_bib19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/00007435-200303000-00008","article-title":"Sexual behavior of older women: results of a random-digit-dialing survey of 2,000 women in the United States","volume":"30","author":"Patel","year":"2003","journal-title":"Sex Transm Dis"},{"key":"2023011111053596400_bib20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/GME.0000000000000134","article-title":"Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial","volume":"21","author":"Simon","year":"2014","journal-title":"Menopause"},{"key":"2023011111053596400_bib21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/009262300278597","article-title":"The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function","volume":"26","author":"Rosen","year":"2000","journal-title":"J\u00a0Sex Marital Ther"},{"key":"2023011111053596400_bib22","first-page":"357","article-title":"Validation of the Female Sexual Distress Scale\u2013Revised for assessing distress in women with hypoactive sexual desire disorder","volume":"5","author":"DeRogatis","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"2023011111053596400_bib23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/gme.0b013e318230e286","article-title":"Characteristics of premenopausal and postmenopausal women with acquired, generalized hypoactive sexual desire disorder: the Hypoactive Sexual Desire Disorder Registry for women","volume":"19","author":"Rosen","year":"2012","journal-title":"Menopause"},{"key":"2023011111053596400_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/13697131003675922","article-title":"Testosterone treatment of HSDD in naturally menopausal women: the ADORE study","volume":"13","author":"Panay","year":"2010","journal-title":"Climacteric"},{"key":"2023011111053596400_bib25","volume-title":"FDA draft guidance for industry. Female sexual dysfunction: clinical development of drug products for treatment","author":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)","year":"2000"},{"key":"2023011111053596400_bib26","first-page":"408","article-title":"Female hypoactive sexual desire disorder: history and current status","volume":"3","author":"Segraves","year":"2006","journal-title":"J\u00a0Sex Med"},{"key":"2023011111053596400_bib27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/00926230590909989","article-title":"Outcome measurement in female sexual dysfunction clinical trials: review and recommendations","volume":"31","author":"Althof","year":"2005","journal-title":"J\u00a0Sex Marital Ther"},{"key":"2023011111053596400_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/713847100","article-title":"Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder","volume":"29","author":"Meston","year":"2003","journal-title":"J\u00a0Sex Marital Ther"},{"key":"2023011111053596400_bib29","first-page":"2237","article-title":"Content validity of the Female Sexual Function Index (FSFI) in pre- and postmenopausal women with hypoactive sexual desire disorder","volume":"8","author":"Revicki","year":"2011","journal-title":"J\u00a0Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609517304319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609517304319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/14\/6\/834\/48525307\/jsm_14_6_834.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/14\/6\/834\/48525307\/jsm_14_6_834.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T14:48:46Z","timestamp":1673448526000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/14\/6\/834\/6973373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6,1]]},"published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2017.03.258","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2017,6]]},"published":{"date-parts":[[2017,6,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder: Results of the PLUMERIA Study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2017.03.258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017, The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.","name":"copyright","label":"Copyright"}]}}